Speaker Profile
M.D., CFO & Head of Corporate Development, Juno Therapeutics
Biography
Steven D. Harr is our Chief Financial Officer and Head of Corporate Development and joined Juno in April 2014. Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley from May 2010 until he joined Juno. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and Co-Head of Global Healthcare Research. Dr. Harr received a B.A. in Economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Cancer immunotherapies, though very promising, face a number of challenges as they strive to reach their full potential. These challenges are both technical and scientific in nature and include sensitivity, specificity, efficacy, and cost. Other issues include overcoming production issues and the high cost of developing these therapeutics. This session will address these challenges through the perspective of respected leaders in the field.
